Kindred Biosciences – Consensus Indicates Potential 205.1% Upside

Broker Ratings

Kindred Biosciences found using ticker (KIN) have now 7 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 14 and 9 calculating the mean target price we have 11.32. Now with the previous closing price of 3.71 this is indicating there is a potential upside of 205.1%. The 50 day MA is 3.83 and the 200 day moving average is 4.19. The company has a market cap of $145m. Visit the company website at:

Kindred Biosciences, a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits
You might also enjoy reading  Kindred Biosciences - Consensus Indicates Potential 2.8% Upside

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index